Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Study Evaluating Enstilar® (Calcipotriene and Betamethasone Dipropionate) Foam, 0.005%/0.064% QD in Psoriasis Patients Being Treated With Biologic Agents

NCT03080545 is registered in ClinicalTrials.gov with Psoriasis Treatment Center of Central New Jersey as lead sponsor.

NCT NCT03080545
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03080545 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Study Evaluating Enstilar® (Calcipotriene and Betamethasone Dipropionate) Foam, 0.005%/0.064% QD in Psoriasis Patients Being Treated With Biologic Agents
Lead sponsor
Psoriasis Treatment Center of Central New Jersey
Phase
Phase 4
Overall status
Completed
Start date
May 1, 2017
Completion date
October 30, 2017
Enrollment
25 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis